Wave Life Sciences director sells shares for tax
Wave Life Sciences, Inc. director Ken Takanashi reported selling 3,864 shares of common stock on August 11, 2026 at a weighted-average price of $6.01 per share, in transactions ranging from $6.01 to $6.03.
Rhea-AI Filing Summary
Wave Life Sciences, Inc. director Ken Takanashi reported selling 3,864 shares of common stock on August 11, 2026 at a weighted-average price of $6.01 per share, in transactions ranging from $6.01 to $6.03. The sale was made solely to cover taxes from restricted stock units vesting that day, pursuant to a previously adopted Rule 10b5-1 trading plan. After the sale, he directly held 20,079 shares and was reported as indirectly associated with 9,606,408 shares held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., for which he disclaims beneficial ownership beyond any pecuniary interest.
Insider Trade Summary 10b5-1
Net Seller: 3,864 shares
Net Sell
2 txns
Insider
TAKANASHI KEN
Role
Director
Sold
3,864 shs ($23K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 3,864 | $6.01 | $23K |
| holding | Common Stock F3, F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 20,079 shares (Direct);
Common Stock — 9,606,408 shares (Indirect, See Footnote)
Footnotes (4)
- F1. On August 11, 2026, the reporting person sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.
- F2. The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3. Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL").
- F4. Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.
Key Figures
Shares sold: 3,864 shares
Weighted-average sale price: $6.01 per share
Sale price range: $6.01 to $6.03 per share
+3 more
6 metrics
Shares sold
3,864 shares
Common stock sold on August 11, 2026 to cover RSU taxes
Weighted-average sale price
$6.01 per share
Weighted-average price for 3,864 shares sold on August 11, 2026
Sale price range
$6.01 to $6.03 per share
Range of prices for multiple sale transactions on August 11, 2026
Direct holdings after sale
20,079 shares
Common stock directly held by Ken Takanashi after the reported sale
Indirect associated holdings
9,606,408 shares
Shares held by SNBL USA and SNBL for which Takanashi may be deemed to have beneficial ownership but disclaims it except for pecuniary interest
10b5-1 plan status
Affirmed
Sales made pursuant to a previously adopted Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 Trading Plan, restricted stock units, weighted-average sale price, beneficial ownership, +1 more
5 terms
Rule 10b5-1 Trading Plan regulatory
"These sales were made pursuant to a previously adopted 10b5-1 Trading Plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted-average sale price financial
"The price reflected is the weighted-average sale price for stock sold"
beneficial ownership regulatory
"may be deemed to beneficially own the reported securities held by SNBL USA and SNBL"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Wave Life Sciences (WVE) report for Ken Takanashi?
Ken Takanashi reported selling 3,864 Wave Life Sciences (WVE) common shares on August 11, 2026. The sale was solely to cover taxes from vesting restricted stock units and was executed under a previously adopted Rule 10b5-1 trading plan.
Was the Wave Life Sciences (WVE) insider sale done under a Rule 10b5-1 plan?
Yes. The sale of 3,864 Wave Life Sciences (WVE) shares on August 11, 2026 was executed pursuant to a previously adopted Rule 10b5-1 trading plan, indicating it was pre-arranged rather than discretionary at the time of sale.
What indirect Wave Life Sciences (WVE) holdings are associated with Ken Takanashi?
The filing reports 9,606,408 Wave Life Sciences (WVE) shares held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd. Ken Takanashi may be deemed to beneficially own them but disclaims beneficial ownership except for any pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
